A small open‑label study tested a gel that contains copper tripeptide‑1 (along with other ingredients) on women with acne scars. Over 45 days the gel noticeably reduced scar visibility and improved skin smoothness and texture, with no reported side effects.

Introduction Skin scars, a natural outcome of dermal injury healing, may seem minor but often lead to significant disfigurement and psychological distress. This study aimed to assess the safety and efficacy of ThriveCo Scar Fader Gel containing Scarcede™ (Anveya Living Private Limited, Bengaluru, India), a proprietary blend of copper tripeptide-1, L-carnitine L-tartrate, alpha-glucosyl hesperidin, and sodium hyaluronate. This synergistic formulation targets multiple scar-improvement mechanisms, offering potential for enhanced skin texture and minimized scar appearance. Method An open-label, interventional, prospective real-world evidence study was conducted to evaluate the clinical safety, efficacy, and in-use tolerability of the test product in females with acne scars. Ethical approval was granted by the Independent Ethics Committee, and informed consent was obtained from all participants. Visible scar changes were assessed using the Manchester Scoring Scale by a dermatologist. Skin texture changes, including smoothness, roughness, and scaliness, were evaluated using VISIOSCAN® VC20 Plus (Courage + Khazaka electronic GmbH, Cologne, Germany). Digital photographs documented progressive scar visibility reduction. Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 29.0.1.0 (Released 2022; IBM Corp., Armonk, New York) and Microsoft® Excel 2019 (Microsoft Corporation, Redmond, Washington), with significance reported at the 5% level. Result The test product reduced scar appearance by 7.17% at day 21 (p<0.001) and 26.57% at day 45 (p<0.0001). Skin smoothness improved by 33.08% at day 21 (p<0.0001) and 44.56% at day 45 (p<0.0001). Skin roughness decreased by 100.86% at day 21 (p<0.0001) and 161.62% at day 45 (p<0.0001). Scaliness reduced by 39.71% at day 21 (p<0.001) and 58.92% at day 45 (p<0.0001). No local or systemic adverse effects were reported. Conclusion ThriveCo Scar Fader Gel with Scarcede™ demonstrated clinical safety and efficacy in scar reduction, supporting smoother, clearer skin without adverse effects and suitable for routine skincare use.